GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biomark Diagnostics Inc (OTCPK:BMKDF) » Definitions » EV-to-Revenue

BMKDF (Biomark Diagnostics) EV-to-Revenue : 178.59 (As of May. 29, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Biomark Diagnostics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Biomark Diagnostics's enterprise value is $20.18 Mil. Biomark Diagnostics's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was $0.11 Mil. Therefore, Biomark Diagnostics's EV-to-Revenue for today is 178.59.

The historical rank and industry rank for Biomark Diagnostics's EV-to-Revenue or its related term are showing as below:

BMKDF' s EV-to-Revenue Range Over the Past 10 Years
Min: 28.83   Med: 67.34   Max: 171.89
Current: 178.86

During the past 11 years, the highest EV-to-Revenue of Biomark Diagnostics was 171.89. The lowest was 28.83. And the median was 67.34.

BMKDF's EV-to-Revenue is ranked worse than
98.57% of 210 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.77 vs BMKDF: 178.86

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-05-29), Biomark Diagnostics's stock price is $0.21725. Biomark Diagnostics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00. Therefore, Biomark Diagnostics's PS Ratio for today is .


Biomark Diagnostics EV-to-Revenue Historical Data

The historical data trend for Biomark Diagnostics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomark Diagnostics EV-to-Revenue Chart

Biomark Diagnostics Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 47.20 - 422.73 119.22 171.26

Biomark Diagnostics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 146.02 171.26 135.43 147.60 120.22

Competitive Comparison of Biomark Diagnostics's EV-to-Revenue

For the Diagnostics & Research subindustry, Biomark Diagnostics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomark Diagnostics's EV-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Biomark Diagnostics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Biomark Diagnostics's EV-to-Revenue falls into.


;
;

Biomark Diagnostics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Biomark Diagnostics's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=20.181/0.113
=178.59

Biomark Diagnostics's current Enterprise Value is $20.18 Mil.
Biomark Diagnostics's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.11 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biomark Diagnostics  (OTCPK:BMKDF) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Biomark Diagnostics's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.21725/0
=

Biomark Diagnostics's share price for today is $0.21725.
Biomark Diagnostics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biomark Diagnostics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Biomark Diagnostics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomark Diagnostics Business Description

Traded in Other Exchanges
Address
130 - 3851 Shell Road, Richmond, BC, CAN, V6X 2W2
Biomark Diagnostics Inc is a Canada-based oncology-focused company. It is engaged in the development of the early-stage cancer diagnostic technology platform. The company develops non-invasive cancer diagnostic solutions which will help to detect, monitor, and assess early cancer treatment. Its research and development are focused on the role that metabolomics plays in early cancer detection. The company's objective is to commercialize its inventive technology. and strive to increase the predictive accuracy in early-stage cancer detection.

Biomark Diagnostics Headlines